Related Experiment Video
Updated: Nov 21, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Impaired Wound Healing with Imatinib Mesylate Therapy
Moritz Ronicke1, Cornelia Erfurt-Berge
1In the Department of Dermatology, University Hospital Erlangen, Germany, Moritz Ronicke, MD, and Cornelia Erfurt-Berge, MD, are Physicians. The authors have disclosed no financial relationships related to this article. Submitted February 16, 2020; accepted in revised form March 26, 2020.
Abstract:
Medication-induced ulcers are generally rare. Although the tyrosine kinase inhibitor imatinib mesylate is frequently prescribed, the occurrence of ulcers related to the medication has not been previously described. Herein, the authors report a case of a patient with impaired wound healing that was attributed to imatinib mesylate treatment. Providers should maintain suspicion for medication-induced ulcers, particularly if treatment for the presumed underlying cause of an ulcer fails.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

